Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Smit

Showing results (331-340 of 692) with videos related to

Pageof 70
Sort By:
Current Medical Research and Opinion|June 16, 2012
Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational studyAlain Vergnenegre, Egbert F Smit, Elisabeth Toy, et al.
British Journal of Cancer|December 17, 2009
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patientsL Vroling, J S W Lind, R R de Haas, et al.
EJNMMI Research|February 10, 2016
Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLCIdris Bahce, Maqsood Yaqub, Hanane Errami, et al.
Lung Cancer (Amsterdam, Netherlands)|February 10, 2015
Second primary lung cancers following a diagnosis of primary head and neck cancerGwendolyn H M J Griffioen, Alexander V Louie, Remco de Bree, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2022
Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trialArd van Veelen, Judith Gulikers, Lizza E L Hendriks, et al.
International Archives of Allergy and Immunology|January 1, 1992
Oral immunization with polyvalent bacterial lysate and infection with Streptococcus pneumoniae: influence on interferon-gamma and PMN elastase concentrations in murine bronchoalveolar lavage fluidG J van Daal, A van 't Veen, K L So, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 22, 2013
KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive valueWouter W Mellema, Anne-Marie C Dingemans, Erik Thunnissen, et al.
Lung Cancer (Amsterdam, Netherlands)|July 1, 2014
Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and functionC Dickhoff, K J Hartemink, P M van de Ven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2020
A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint InhibitorsMirte Muller, Karlijn Hummelink, Daan P Hurkmans, et al.
Current Medical Research and Opinion|October 15, 2010
Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational studyDenis Moro-Sibilot, Alain Vergnenegre, Egbert F Smit, et al.
Pageof 70

Showing results (331-340 of 692) with videos related to

Sort By:
Pageof 70
Current Medical Research and Opinion|June 16, 2012
Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational studyAlain Vergnenegre, Egbert F Smit, Elisabeth Toy, et al.
British Journal of Cancer|December 17, 2009
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patientsL Vroling, J S W Lind, R R de Haas, et al.
EJNMMI Research|February 10, 2016
Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLCIdris Bahce, Maqsood Yaqub, Hanane Errami, et al.
Lung Cancer (Amsterdam, Netherlands)|February 10, 2015
Second primary lung cancers following a diagnosis of primary head and neck cancerGwendolyn H M J Griffioen, Alexander V Louie, Remco de Bree, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2022
Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trialArd van Veelen, Judith Gulikers, Lizza E L Hendriks, et al.
International Archives of Allergy and Immunology|January 1, 1992
Oral immunization with polyvalent bacterial lysate and infection with Streptococcus pneumoniae: influence on interferon-gamma and PMN elastase concentrations in murine bronchoalveolar lavage fluidG J van Daal, A van 't Veen, K L So, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 22, 2013
KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive valueWouter W Mellema, Anne-Marie C Dingemans, Erik Thunnissen, et al.
Lung Cancer (Amsterdam, Netherlands)|July 1, 2014
Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and functionC Dickhoff, K J Hartemink, P M van de Ven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2020
A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint InhibitorsMirte Muller, Karlijn Hummelink, Daan P Hurkmans, et al.
Current Medical Research and Opinion|October 15, 2010
Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational studyDenis Moro-Sibilot, Alain Vergnenegre, Egbert F Smit, et al.
Pageof 70